Skip to main content

Analysts Offer Insights on Consumer Cyclical Companies: Whirlpool (WHR) and SharkNinja, Inc. (SN)

Tipranks - Wed Jan 14, 3:28AM CST

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Whirlpool (WHRResearch Report) and SharkNinja, Inc. (SNResearch Report).

Claim 70% Off TipRanks Premium

Whirlpool (WHR)

RBC Capital analyst Michael Dahl maintained a Sell rating on Whirlpool on January 8 and set a price target of $51.00. The company’s shares closed last Monday at $83.94.

According to TipRanks.com, Dahl is a 5-star analyst with an average return of 9.6% and a 60.5% success rate. Dahl covers the Industrial Goods sector, focusing on stocks such as Fortune Brands Innovations, SiteOne Landscape Supply, and Builders Firstsource. ;'>

The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Whirlpool with a $64.50 average price target.

See today’s best-performing stocks on TipRanks >>

SharkNinja, Inc. (SN)

William Blair analyst Phillip Blee maintained a Buy rating on SharkNinja, Inc. today. The company’s shares closed last Monday at $123.68.

According to TipRanks.com, Blee is a 5-star analyst with an average return of 21.7% and a 64.9% success rate. Blee covers the NA sector, focusing on stocks such as Somnigroup International, Floor & Decor Holdings, and Driven Brands Holdings. ;'>

Currently, the analyst consensus on SharkNinja, Inc. is a Strong Buy with an average price target of $137.00, which is a 13.2% upside from current levels. In a report issued on January 7, TipRanks – xAI also reiterated a Buy rating on the stock with a $134.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.